Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

NCT00988013 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT00988013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00988013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Lead sponsor
University of Illinois at Chicago
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2009
Completion date
February 29, 2016
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoblastic leukemia, non hodgkins lymphoma